UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144
Benzinga Newsdesk 1 month ago
NewsInitiationAnalyst RatingsPrice Target
UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.
UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.